Slide
Securing
Connections
Corporate Profile
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.
Minimum 15 minutes delayed. Source:
Latest Presentations
More information is coming soon.
Press Releases
September 17, 2024
September 3, 2024
Events & Presentations
September 3, 2024 at 4:30 PM EDT
June 18, 2024 at 11:30 AM EDT
June 12, 2024 at 2:00 PM EDT